newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and